In a groundbreaking move, the Novo Nordisk Foundation’s Cellerator facility has been established to accelerate cell therapy development. Led by CEO Mads Krogsgaard Thomsen, the facility aims to bridge the gap between research experiments and clinical trials, positioning itself as a key player in the European cell therapy landscape. This initiative not only holds promise for Danish innovation but also sets a new standard for advancing cell-based treatments on a broader scale. Stay tuned as Cellerator paves the way for transformative advancements in the field of cell therapy.
Read more about this — here
